An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
Status
Completed
Conditions
Malignant Melanoma
Details and patient eligibility
About
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.
Enrollment
403 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Adult patients, >/= 18 years of age at diagnosis
- Histologically confirmed new diagnosis of unresectable or metastatic melanoma
- Patients with tumor samples available for assessment of BRAF V600 mutation
Exclusion criteria
- Prior systemic therapy for metastatic disease
- Participation in interventional clinical trials
Trial design
403 participants in 1 patient group
Cohort
Trial contacts and locations
24
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems